
Aplastic anaemia is a rare but potentially fatal bone marrow failure syndrome characterised by peripheral blood pancytopenia. Allogeneic haematopoietic stem cell transplantation offers curative potential in eligible patients, while immunosuppressive therapy with anti-thymocyte globulin and cyclosporine remains the standard for those without a matched donor. Eltrombopag combinations and newer TPO-receptor agonists have shown improved response rates in refractory disease.